335 related articles for article (PubMed ID: 30611312)
1. Safety and efficacy of infliximab in the treatment of refractory uveoretinitis in Behçet's disease: a large-scale, long-term postmarketing surveillance in Japan.
Ohno S; Umebayashi I; Matsukawa M; Goto T; Yano T
Arthritis Res Ther; 2019 Jan; 21(1):2. PubMed ID: 30611312
[TBL] [Abstract][Full Text] [Related]
2. Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Behçet's disease with refractory uveoretinitis.
Ohno S; Nakamura S; Hori S; Shimakawa M; Kawashima H; Mochizuki M; Sugita S; Ueno S; Yoshizaki K; Inaba G
J Rheumatol; 2004 Jul; 31(7):1362-8. PubMed ID: 15229958
[TBL] [Abstract][Full Text] [Related]
3. [Effects and safety of infliximab administration in refractory uveoretinitis with Behçet's disease].
Tanaka H; Sugita S; Yamada Y; Kawaguchi T; Iwanaga Y; Kamoi K; Yokota M; Takase H; Mochizuki M
Nippon Ganka Gakkai Zasshi; 2010 Feb; 114(2):87-95. PubMed ID: 20187505
[TBL] [Abstract][Full Text] [Related]
4. Real-world efficacy of adalimumab and infliximab for refractory intestinal Behçet's disease.
Sugimura N; Mizoshita T; Sugiyama T; Togawa S; Miyaki T; Suzuki T; Tanida S; Kataoka H; Sasaki M
Dig Liver Dis; 2019 Jul; 51(7):967-971. PubMed ID: 30872086
[TBL] [Abstract][Full Text] [Related]
5. Multicenter study of infliximab for refractory uveoretinitis in Behçet disease.
Okada AA; Goto H; Ohno S; Mochizuki M;
Arch Ophthalmol; 2012 May; 130(5):592-8. PubMed ID: 22652845
[TBL] [Abstract][Full Text] [Related]
6. Long-term efficacy, safety, and cumulative retention rate of antitumor necrosis factor-alpha treatment for patients with Behcet's uveitis: A systematic review and meta-analysis.
Guan X; Zhao Z; Xin M; Xia G; Yang Q; Fu M
Int J Rheum Dis; 2024 Feb; 27(2):e15096. PubMed ID: 38402428
[TBL] [Abstract][Full Text] [Related]
7. [Effectiveness of infliximab in patients with Behçet syndrome and severe uveoretinitis. Report of five cases].
Merino G; Varas G; Díaz G; Gutiérrez M; Massardo L; Pacheco D; Villarroel F; Cuchacovich M
Rev Med Chil; 2006 Jul; 134(7):875-82. PubMed ID: 17130971
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of the long-term efficacy and safety of infliximab treatment for uveitis in Behçet's disease: a multicenter study.
Takeuchi M; Kezuka T; Sugita S; Keino H; Namba K; Kaburaki T; Maruyama K; Nakai K; Hijioka K; Shibuya E; Komae K; Hori J; Ohguro N; Sonoda KH; Mizuki N; Okada AA; Ishibashi T; Goto H; Mochizuki M
Ophthalmology; 2014 Oct; 121(10):1877-84. PubMed ID: 24950593
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of Infliximab for Early Remission Induction in Refractory Uveoretinitis Associated with Behçet Disease: A 2-year Follow-up Study.
Keino H; Okada AA; Watanabe T; Nakayama M; Nakamura T
Ocul Immunol Inflamm; 2017 Feb; 25(1):46-51. PubMed ID: 27767359
[TBL] [Abstract][Full Text] [Related]
10. Decreased ocular inflammatory attacks and background retinal and disc vascular leakage in patients with Behcet's disease on infliximab therapy.
Keino H; Okada AA; Watanabe T; Taki W
Br J Ophthalmol; 2011 Sep; 95(9):1245-50. PubMed ID: 21183514
[TBL] [Abstract][Full Text] [Related]
11. Long-term efficacy of early infliximab-induced remission for refractory uveoretinitis associated with Behçet's disease.
Keino H; Watanabe T; Nakayama M; Komagata Y; Fukuoka K; Okada AA
Br J Ophthalmol; 2021 Nov; 105(11):1525-1533. PubMed ID: 32972915
[TBL] [Abstract][Full Text] [Related]
12. Infliximab treatment for ocular and extraocular manifestations of Behçet's disease.
Accorinti M; Pirraglia MP; Paroli MP; Priori R; Conti F; Pivetti-Pezzi P
Jpn J Ophthalmol; 2007; 51(3):191-6. PubMed ID: 17554481
[TBL] [Abstract][Full Text] [Related]
13. Postmarketing surveillance of the safety profile of infliximab in 5000 Japanese patients with rheumatoid arthritis.
Takeuchi T; Tatsuki Y; Nogami Y; Ishiguro N; Tanaka Y; Yamanaka H; Kamatani N; Harigai M; Ryu J; Inoue K; Kondo H; Inokuma S; Ochi T; Koike T
Ann Rheum Dis; 2008 Feb; 67(2):189-94. PubMed ID: 17644554
[TBL] [Abstract][Full Text] [Related]
14. Long-term efficacy of infliximab on background vascular leakage in patients with Behçet's disease.
Keino H; Okada AA; Watanabe T; Taki W
Eye (Lond); 2014 Sep; 28(9):1100-6. PubMed ID: 24946845
[TBL] [Abstract][Full Text] [Related]
15. Infliximab therapy in Behçet's uveitis.
Alizadegan F; Yalcinbayir O; Ucan Gunduz G; Pehlivan Y
J Fr Ophtalmol; 2022 Nov; 45(9):1036-1041. PubMed ID: 36150991
[TBL] [Abstract][Full Text] [Related]
16. Long-term outcomes of infliximab in patients with Behçet's disease-associated uveitis.
Yamana S; Hasegawa E; Takeda A; Yawata N; Sonoda KH
Int Ophthalmol; 2023 Mar; 43(3):937-944. PubMed ID: 36057758
[TBL] [Abstract][Full Text] [Related]
17. Clinical background comparison of patients with and without ocular inflammatory attacks after initiation of infliximab therapy.
Yoshida A; Kaburaki T; Okinaga K; Takamoto M; Kawashima H; Fujino Y
Jpn J Ophthalmol; 2012 Nov; 56(6):536-43. PubMed ID: 23053631
[TBL] [Abstract][Full Text] [Related]
18. A 10-year follow-up of infliximab monotherapy for refractory uveitis in Behçet's syndrome.
Horiguchi N; Kamoi K; Horie S; Iwasaki Y; Kurozumi-Karube H; Takase H; Ohno-Matsui K
Sci Rep; 2020 Dec; 10(1):22227. PubMed ID: 33335139
[TBL] [Abstract][Full Text] [Related]
19. INTRAVITREAL INFLIXIMAB IN REFRACTORY UVEITIS IN BEHCET'S DISEASE: A Safety and Efficacy Clinical Study.
Hamza MM; Macky TA; Sidky MK; Ragab G; Soliman MM
Retina; 2016 Dec; 36(12):2399-2408. PubMed ID: 27870802
[TBL] [Abstract][Full Text] [Related]
20. Long-term efficacy of infliximab in refractory posterior uveitis of Behcet's disease: a 24-month follow-up study.
Niccoli L; Nannini C; Benucci M; Chindamo D; Cassarà E; Salvarani C; Cimino L; Gini G; Lenzetti I; Cantini F
Rheumatology (Oxford); 2007 Jul; 46(7):1161-4. PubMed ID: 17478466
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
